121 related articles for article (PubMed ID: 25714667)
1. Factors influencing the success of radioiodine therapy in patients with Graves' disease.
Šfiligoj D; Gaberšček S; Mekjavič PJ; Pirnat E; Zaletel K
Nucl Med Commun; 2015 Jun; 36(6):560-5. PubMed ID: 25714667
[TBL] [Abstract][Full Text] [Related]
2. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
3. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
Markovic V; Eterovic D
J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
[TBL] [Abstract][Full Text] [Related]
4. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
6. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
[TBL] [Abstract][Full Text] [Related]
10. The outcome of 131I treatment in Graves' patients pretreated or not with methimazole.
Pirnat E; Zaletel K; Gaberšček S; Hojker S
Hell J Nucl Med; 2011; 14(1):25-9. PubMed ID: 21512661
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
Haase A; Bähre M; Lauer I; Meller B; Richter E
Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
[TBL] [Abstract][Full Text] [Related]
12. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover.
de Jong JA; Verkooijen HM; Valk GD; Zelissen PM; de Keizer B
Clin Nucl Med; 2013 Jun; 38(6):401-6. PubMed ID: 23579983
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
15. Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose.
Massaro F; Vera L; Schiavo M; Lagasio C; Caputo M; Bagnasco M; Minuto F; Giusti M
J Endocrinol Invest; 2007 Apr; 30(4):318-22. PubMed ID: 17556869
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
17. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
18. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
[TBL] [Abstract][Full Text] [Related]
19. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
Stachura A; Gryn T; Kałuża B; Budlewski T; Franek E
BMC Endocr Disord; 2020 Jun; 20(1):77. PubMed ID: 32487052
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
